Hengyu Medical Secures Nearly RMB 100 Million in 2025 to Accelerate Development of Intravascular Imaging and Therapeutic Products

Smart Medical Device Network NewsRecently, Horimed Technology Co., Ltd. (hereinafter referred to asHorimed Announces Completion of Nearly 100 Million Yuan in Financing. This round of financing was jointly invested by Guanghua Wutong, Chengdu Science and Technology Investment, and Zhongtian Weiyi. Xingqiao Capital served as the long-term exclusive financial advisor. Notably, this is the company's second round of financing this year.

Data shows that Horimed Technology Co., Ltd. was founded in2016Year, Focused on Intravascular Ultrasound(IntravascularUltrasound, IVUS)Equipment and Catheters, Optical Coherence Tomography(Optical CoherenceTomography, OCT)Equipment and Catheters,IVUS/OCTAll-in-one dual-catheter system, based onIVUSAndOCTNon-invasive Fractional Flow Reserve(Fractional FlowReserve, FFR)Platform, IntegrationOCTCompared with near-infrared spectroscopy (Near-Infrared Spectroscopy,NIRS) Single-source Dual-modalOCT-NIRSIndependent research, development, production, and sales of technologies and intravascular laser plaque ablation technologies, mastering optical, ultrasound, and catheter platform technologies, committed to providing an integrated pan-vascular solution based on imaging products for doctors and patients.

It is reported that the company has a high level of endoscopyOCTTechnology, AngiographyOCTTechnology and Polarization SensitiveOCTTechnical and other functionsOCTTechnology, the company's core product cardiovascularOCTEquipment and optical imaging catheters, intravascular ultrasound (IVUS) The system and imaging catheter both possess independent intellectual property rights and core manufacturing processes.

At the same time, itsWith a well-established R&D team and sales team, the proportion of employees with a Ph.D. degree is3%, Proportion of Master's Degree Holders25%, Proportion of Bachelor's Degree50%, bringing together talents graduated from universities such as the University of Washington and the University of Southern California. The professional research fields cover optics, mechanics, electronics, software, and medical, with rich and solid R&D experience covering the entire set.OCT、IVUSAndOCT/IVUSAll-in-one device and consumables, with a strong technical reserve in intravascular laser ablation technology.

And the companyWith a strong technical foundation in optics, ultrasound, core imaging algorithms, and medical catheter technology, particularly in the cardiovascular field.OCT、IVUSand has established a comprehensive R&D system in the field of multimodal imaging. Core experts have been engaged in related research for nearly20Year, with R&D laboratories in China and abroad, maintaining close cooperation with global bio-imaging experts, and establishing strategic partnerships with multiple universities, research institutes, and hospitals.

Moreover, it possesses strong continuous R&D capabilities and advanced manufacturing technology.Focused on the research and development of products and equipment in the field of endoluminal diagnosis and treatment, a complete R&D system has been established. At this stage, Horimed has nearly50Number of invention patents, including both granted and pending patents100Remaining items.

Horimed has established profound cooperative relationships with more than ten hospitals, including the Second Affiliated Hospital of Harbin Medical University, the Second Affiliated Hospital of Zhejiang University, the General Hospital of the People's Liberation Army, Sir Run Run Shaw Hospital of Zhejiang University, the Tenth Hospital Affiliated to Tongji University, the First Affiliated Hospital of Xi'an Jiaotong University, Hangzhou First People’s Hospital, and Fuwai Hospital, among others. It has also entered into strategic cooperation with institutions such as Tianjin University. Meanwhile, Horimed is undertaking multiple scientific research projects, including two projects funded by the National Natural Science Foundation of China and key projects under the Tianjin Key Research and Development Program.

According to the data,ChinaIVUSThe market has long been dominated by international giants, but2022Became a domestic substitute in year“Watershed”. Prior to this, Philips exceeded80%The market share forms a monopoly, with brands such as Boston Scientific occupying the remaining market;2022After the year, domestic manufacturers such as NorthX and Horimed have successively achieved technological breakthroughs, and the market pattern has begun to be reshaped.

From the current competitive situation, the market presents“Foreign Investment Dominates, Domestic Production Rises”Characteristics，2025Data from the first half of the year shows that Boston Scientific still leads with67.99%The share ranks first, Philips dropped to15.17%; Among the domestically produced products, Northcore Technology with5.32%Horimed Technology Co., Ltd. (2.84%), Horimed (2.15%) Following closely, Chinese manufacturers account for approximately17%。

In addition,IVUSTechnology is moving towards“Intelligent, Integrated, Minimally Invasive”Directional Evolution: The current focus of industry competition has shifted from traditional hardware parameter competition to“Technology+Algorithm”Comprehensive solution competition.

AIEmpowerment Becomes the Core Breakthrough Point，2025Launched inAVVIGO+System, etc.AI-IVUSPlatform, capable of achieving three major functional upgrades: real-time plaque qualitative classification (accuracy >95%), Intelligent Stent Size Recommendation (Consistency with Doctor's Decision Reaches89%), Automatic early warning of intraoperative wall-sticking risk (Sensitivity92%）。

At the same time,The Rise of Multimodal Imaging Fusion Technology，WillIVUSCompared with Optical Coherence Tomography (OCT）、Coronary Flow Reserve Fraction (FFR) Combine to form“Anatomy+Function”Comprehensive evaluation system. For exampleIVUS-OCTThe fusion system can simultaneously provide information on plaque microstructure and macro morphology.FFR-IVUSCombined assessment can more accurately determine the degree of functional stenosis of lesions, and such technologies have become a new direction for high-end procurement in tertiary hospitals.

In addition,Minimally Invasive and Peripheral Expansion，Chinese manufacturers begin to layout in the peripheral vascular intravascular ultrasound field, with NorthXin Technology...2025Year7Approved in China for the first peripheralIVUSCatheter, which can be used for the evaluation of lesions in carotid arteries, renal arteries, etc., fills the gap of domestically produced products in the peripheral market. In addition, the miniaturized probe (diameter <1mm)'s research and development progress provides possibilities for the diagnosis of cerebrovascular and other small vessel diseases.

Despite the strong momentum of domestically produced alternatives, manufacturers still face three core challenges: First, reliance on imports for key components such as high-end chips and high-frequency probes highlights risks to supply chain security; second, insufficient brand recognition, with tertiary hospitals' core departments still favoring foreign products; third, significant pressure from R&D investment.

Editor's Express

1

Enterprise interviews, in-depth reporting and promotion of products and technologies, industry report consulting, contributions;

2

Contact: 13714842321 (Same on WeChat)